Comparative Pharmacology
Head-to-head clinical analysis: HEPARIN SODIUM 25 000 UNITS IN SODIUM CHLORIDE 0 45 versus MAGNESIUM SULFATE IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HEPARIN SODIUM 25 000 UNITS IN SODIUM CHLORIDE 0 45 versus MAGNESIUM SULFATE IN PLASTIC CONTAINER.
HEPARIN SODIUM 25,000 UNITS IN SODIUM CHLORIDE 0.45% vs MAGNESIUM SULFATE IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Heparin binds to antithrombin III, causing a conformational change that accelerates the inactivation of thrombin (factor IIa) and factor Xa, and to a lesser extent factors IXa, XIa, and XIIa, thereby inhibiting coagulation.
Magnesium sulfate causes decreased release of acetylcholine at the neuromuscular junction, reducing muscle contractility. It also blocks calcium channels, leading to vasodilation and anticonvulsant effects.
5000 units IV bolus followed by continuous IV infusion at 1300 units/hour, adjusted based on aPTT.
IV: 1-4 g as a 10-20% solution, rate not exceeding 1 g/min; for eclampsia: 4-5 g IV bolus then 1-2 g/hour IV infusion.
None Documented
None Documented
Terminal elimination half-life: 1-2 hours (dose-dependent, prolonged at high doses); clinical context: half-life increases with dose (nonlinear pharmacokinetics), up to 2.5-3 hours with 25,000 units.
Normal renal function: 4–6 hours (terminal). In oliguria or anuria, half-life may extend to >24 hours, requiring dose adjustment.
Primarily hepatic metabolism (partial, via desulfation and depolymerization) and reticuloendothelial system uptake; renal excretion of metabolites; <1% unchanged in urine.
Primarily renal (glomerular filtration); >90% excreted unchanged in urine. Biliary/fecal elimination is negligible (<1%).
Category A/B
Category C
Electrolyte
Electrolyte